BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27150271)

  • 1. Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis.
    Iwamoto N; Takanashi M; Hamada A; Shimada T
    Biol Pharm Bull; 2016 Jul; 39(7):1187-94. PubMed ID: 27150271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis.
    Iwamoto N; Shimada T; Terakado H; Hamada A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():9-16. PubMed ID: 27155936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis.
    Iwamoto N; Umino Y; Aoki C; Yamane N; Hamada A; Shimada T
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):46-50. PubMed ID: 26830079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab.
    Iwamoto N; Takanashi M; Umino Y; Aoki C; Hamada A; Shimada T
    Bioanalysis; 2016 May; 8(10):1009-20. PubMed ID: 26972866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
    Iwamoto N; Takanashi M; Yokoyama K; Yonezawa A; Denda M; Hashimoto M; Tanaka M; Ito H; Matsuura M; Yamamoto S; Honzawa Y; Matsubara K; Shimada T
    J Immunol Methods; 2019 Sep; 472():44-54. PubMed ID: 31201793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.
    Iwamoto N; Yonezawa A; Matsubara K; Shimada T
    J Pharm Biomed Anal; 2019 Feb; 164():467-474. PubMed ID: 30447535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.
    Iwamoto N; Hamada A; Shimada T
    Anal Biochem; 2018 Jan; 540-541():30-37. PubMed ID: 29128290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.
    Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
    Pharmacol Res Perspect; 2018 Jul; 6(4):e00422. PubMed ID: 30062014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach.
    Iwamoto N; Shimada T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):19-24. PubMed ID: 30392772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
    Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
    Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients.
    Iwamoto N; Shimomura A; Tamura K; Hamada A; Shimada T
    J Pharm Biomed Anal; 2017 Oct; 145():33-39. PubMed ID: 28648785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Indicated LC-MS/MS Bioanalysis of Therapeutic Antibodies.
    Iwamoto N; Shimada T
    Methods Mol Biol; 2022; 2313():187-205. PubMed ID: 34478139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis.
    Iwamoto N; Shimada T; Umino Y; Aoki C; Aoki Y; Sato TA; Hamada A; Nakagama H
    Analyst; 2014 Feb; 139(3):576-80. PubMed ID: 24326404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics.
    Iwamoto N; Koguchi Y; Yokoyama K; Hamada A; Yonezawa A; Piening BD; Tran E; Fox BA; Redmond WL; Shimada T
    Analyst; 2022 Sep; 147(19):4275-4284. PubMed ID: 35997223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast LC-MS/MS analysis of free oxysterols derived from reactive oxygen species in human plasma and carotid plaque.
    Helmschrodt C; Becker S; Schröter J; Hecht M; Aust G; Thiery J; Ceglarek U
    Clin Chim Acta; 2013 Oct; 425():3-8. PubMed ID: 23827692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
    de Dios K; Manibusan A; Marsden R; Pinkstaff J
    J Immunol Methods; 2013 Oct; 396(1-2):1-7. PubMed ID: 23933323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of plasma concentration of Belimumab by LC-MS/MS: Method development, validation, and clinical application.
    Marin C; Noé G; Schlemmer D; Beaulieu Q; Robidou P; Mansour B; Hirtz C; Vialaret J; Antignac M; Moyon Q; Benameur N; Amoura Z; Zahr N
    J Pharm Biomed Anal; 2023 Nov; 236():115730. PubMed ID: 37734255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma.
    Millet A; Khoudour N; Lebert D; Machon C; Terrier B; Blanchet B; Guitton J
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33806585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.
    Peng K; Xu K; Liu L; Hendricks R; Delarosa R; Erickson R; Budha N; Leabman M; Song A; Kaur S; Fischer SK
    MAbs; 2014; 6(6):1500-8. PubMed ID: 25484037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High throughput and sensitive determination of trazodone and its primary metabolite, m-chlorophenylpiperazine, in human plasma by liquid chromatography-tandem mass spectrometry.
    Patel BN; Sharma N; Sanyal M; Shrivastav PS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):44-54. PubMed ID: 18621591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.